FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
Not Approved
This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.
Evidence visual
Selank evidence and risk matrix
intermediate researcher fit
Evidence
Tier B-C
Risk
med high
Regulatory
not approved
WADA
unknown
FDA
flagged
Route
intranasal
Mixed evidence profile. Useful for comparison, not a standalone protocol decision.
Overview
Selank is a tuftsin analogue peptide with proposed neuroactive effects including allosteric modulation of the GABAergic system. A human GAD study reports intranasal administration of 2700 µg/day. Gene-expression changes consistent with complex neuroactive effects have been described. Limited Western regulatory framing; treat as higher scrutiny.
Decision path
Where Selank fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether Selank belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
Gene-expression changes consistent with neuroactive effects; proposed allosteric modulation of GABAergic system.
intranasal
Human GAD study: intranasal 2700 µg/day.
Anxiolytic/calm focus effects reported in limited clinical settings.
Some rapid responders described in clinical abstracts, but not broad RCT-grade evidence.
No established label.
Limited Western regulatory data; higher scrutiny warranted.
Animal diazepam interaction explored; do not translate to human guidance.
Cost at a glance
Typical cycle cost
€20.64
Estimated monthly
€27.52
Protocol style
1-3 week burst
Short burst
Estimate confidence
High confidence
Assumes roughly 3 mg–9 mg per cycle, using 1 tracked affiliated listing.
Reflects short anxiolytic/nootropic runs with breaks.
Known Interactions
FDA notes limited safety-related information and compounding immunogenicity/impurity concerns for both.
CNS-active peptide combination; limited human safety basis.
Neuroactive stack with limited direct human interaction evidence.
CNS-active experimental pairing with uncertain interaction profile.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for Selank.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.